|
|
Blood, 15 October 2007, Vol. 110, No. 8, pp. 2907-2915.
Prepublished online as a Blood First Edition Paper on July 16, 2007; DOI 10.1182/blood-2007-05-089086.
 Previous Article | Next Article 
Submitted May 9, 2007
Accepted July 8, 2007
Interferon- promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis
Michael F Denny, Seth Thacker, Hemal Mehta, Emily C Somers, Todd Dodick, Franck J Barrat, W. Joseph McCune, and Mariana J Kaplan*
Division of Rheumatology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, United States
Graduate Program in Immunology, University of Michigan Medical School, Ann Arbor, MI, United States
Dynavax Technologies, Berkeley, CA, United States
* Corresponding author; email: makaplan{at}umich.edu.
Individuals with systemic lupus erythematosus (SLE) have a striking increase in premature atherosclerosis of unclear etiology. Accelerated endothelial cell apoptosis occurs in SLE and correlates with endothelial dysfunction. Endothelial progenitor cells (EPCs) and myelomonocytic circulating angiogenic cells (CACs) are crucial in blood vessel repair post-vascular damage, and decreased levels/abnormal function of EPCs/CACs are established atherosclerosis risk factors. We investigated if vascular repair is impaired in SLE. We report that SLE patients display abnormal phenotype and function of EPCs/CACs, characterized by significant decreases in the number of circulating EPCs (310±50 EPCs/ml of blood in SLE versus 639±102 in controls) and significant impairments in the capacity of EPCs/CACs to differentiate into mature ECs and synthesize adequate levels of the proangiogenic molecules vascular endothelial growth factor (VEGF) and hepatic growth factor (HGF). These abnormalities are triggered by interferon- (IFN- ) which induces EPC and CAC apoptosis and skews myeloid cells towards non-angiogenic phenotypes. Lupus EPCs/CACs have increased IFN- expression and their supernatants promote higher induction of IFN-inducible genes. Importantly, neutralization of IFN pathways restores a normal EPC/CAC phenotype in lupus. SLE is characterized by an imbalance between endothelial cell damage and repair triggered by type I IFNs which might promote accelerated atherosclerosis.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
W. Zhao, S. G. Thacker, J. B. Hodgin, H. Zhang, J. H. Wang, J. L. Park, A. Randolph, E. C. Somers, S. Pennathur, M. Kretzler, et al.
The Peroxisome Proliferator-Activated Receptor {gamma} Agonist Pioglitazone Improves Cardiometabolic Risk and Renal Inflammation in Murine Lupus
J. Immunol.,
August 15, 2009;
183(4):
2729 - 2740.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. E. Westerweel, R. H. W. M. Derksen, and M. C. Verhaar
Comment on: Systemic lupus erythematosus patients exhibit functional deficiencies of endothelial progenitor cells
Rheumatology,
April 1, 2009;
48(4):
453 - 453.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Grisar, J. S. Smolen, and on behalf of the authors
Comment on: Systemic lupus erythematosus patients exhibit functional deficiencies of endothelial progenitor cells: reply
Rheumatology,
April 1, 2009;
48(4):
453 - 454.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J H W Distler, Y Allanore, J Avouac, R Giacomelli, S Guiducci, F Moritz, A Akhmetshina, U A Walker, A Gabrielli, U Muller-Ladner, et al.
EULAR Scleroderma Trials and Research group statement and recommendations on endothelial precursor cells
Ann Rheum Dis,
February 1, 2009;
68(2):
163 - 168.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
